Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company focused on improving surgical robotics, has announced its plans to report second quarter 2024 financial results on August 12, 2024, after the market closes. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate in the call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using the access code 997268. Additionally, a live and archived webcast of the event will be available on the company's investor relations website.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced a 1-for-30 reverse stock split for its Class A and Class B common stock, effective June 12, 2024. This move aims to raise the company's share price to meet NYSE listing requirements. Post-split, Class A common stock will reduce from approximately 156.76 million to about 5.23 million shares, and Class B from 19.62 million to roughly 654,000 shares. Trading on a post-split basis begins on June 13, 2024, under the symbol 'RBOT'. The split will uniformly affect all stockholders without changing ownership percentages, except for fractional shares, which will be paid in cash. Warrants will also be adjusted, with the exercise price changing to $345 per share.
Vicarious Surgical Inc. (RBOT) reported its first-quarter 2024 financial results, showcasing a decrease in operating expenses, R&D expenses, general and administrative expenses, and sales and marketing expenses compared to the previous year. The company reported an adjusted net loss of $15.1 million, equating to a loss of $0.09 per share, and a GAAP net loss of $17.0 million, or a net loss per share of $0.10 for the same period. Vicarious Surgical had $84.1 million in cash and investments as of March 31, 2024, with a cash burn rate of $14.1 million for the first quarter. The company reiterated its expected full-year 2024 cash burn of approximately $50 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.